Vitura Health Ltd (ASX: VIT) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Vitura Health Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Vitura Health Ltd (ASX: VIT)
Latest News
Share Gainers
3 ASX All Ordinaries shares surging more than 10% today
Share Gainers
Why Audinate, Endeavour, IAG, and Vitura Health shares are charging higher
Share Gainers
Why Beach, Coles, Cronos Australia, and Woolworths shares are pushing higher
Share Fallers
Why Cronos Australia, Pilbara Minerals, Sayona Mining, and Strike Energy are dropping
Share Fallers
Why Cronos Australia, Mesoblast, Sims, and WAM Research are dropping
Cannabis Shares
ASX cannabis share Cronos has soared 80% in a month. What's going on?
Share Gainers
Why Air New Zealand, Cronos, Soul Patts, and Viva Energy shares are pushing higher
Broker Notes
Bell Potter slaps buy rating on this profitable, dividend-paying ASX cannabis share
Earnings Results
Guess which company just became the first ASX cannabis share to pay a dividend
Cannabis Shares
Can ASX cannabis shares ever fully recover?
Earnings Results
Guess which ASX cannabis share just rocketed 30%
Cannabis Shares
Green shoots or just weeds? The outlook for ASX cannabis shares in FY23
Dividend Payment History Data provided by Morningstar.
Ex-Date | Amount | Franking | Type | Payable |
---|---|---|---|---|
04 Sep 2023 | $0.0100 | 100.00% | Final | 28 Sep 2023 |
16 Sep 2022 | $0.0100 | 100.00% | Final | 11 Oct 2022 |
VIT ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Vitura Health Ltd
Vitura Health Ltd is focused on creating medicinal cannabis products and digital health solutions that connect and strengthen the ecosystem between patients, prescribers, pharmacists, and suppliers. The company has two business segments namely, Sales and distribution (involving the sale and distribution of medical products including medicinal cannabis, psychedelic drugs, and smoking cessation products) and Clinics and services (involving the operation of medicinal cannabis clinics and the provision of related services). The company generates the majority of its revenue from the Sales and distribution segment. Geographically the company generates the majority of its revenue from Australia.
VIT Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
20 Nov 2024 | $0.10 | $0.00 | 0.00% | 2,881 | $0.10 | $0.10 | $0.10 |
19 Nov 2024 | $0.10 | $0.00 | 0.00% | 134,917 | $0.09 | $0.10 | $0.09 |
18 Nov 2024 | $0.09 | $0.00 | 0.00% | 64,187 | $0.10 | $0.10 | $0.09 |
15 Nov 2024 | $0.09 | $0.00 | 0.00% | 330,098 | $0.10 | $0.10 | $0.09 |
14 Nov 2024 | $0.10 | $0.00 | 0.00% | 7,766 | $0.10 | $0.10 | $0.10 |
13 Nov 2024 | $0.10 | $0.00 | 0.00% | 614,864 | $0.10 | $0.10 | $0.10 |
12 Nov 2024 | $0.10 | $0.00 | 0.00% | 51,671 | $0.10 | $0.10 | $0.10 |
11 Nov 2024 | $0.10 | $0.00 | 0.00% | 114,301 | $0.10 | $0.10 | $0.10 |
08 Nov 2024 | $0.10 | $0.00 | 0.00% | 138,408 | $0.10 | $0.10 | $0.10 |
07 Nov 2024 | $0.10 | $0.00 | 0.00% | 816,028 | $0.10 | $0.10 | $0.10 |
06 Nov 2024 | $0.10 | $0.00 | 0.00% | 97,496 | $0.10 | $0.10 | $0.10 |
05 Nov 2024 | $0.10 | $0.00 | 0.00% | 283,879 | $0.10 | $0.10 | $0.10 |
04 Nov 2024 | $0.10 | $0.00 | 0.00% | 126,850 | $0.10 | $0.10 | $0.10 |
01 Nov 2024 | $0.10 | $-0.01 | -9.52% | 278,915 | $0.11 | $0.11 | $0.10 |
31 Oct 2024 | $0.11 | $0.00 | 0.00% | 25,066 | $0.11 | $0.11 | $0.10 |
30 Oct 2024 | $0.11 | $0.00 | 0.00% | 207,215 | $0.11 | $0.11 | $0.11 |
29 Oct 2024 | $0.11 | $0.01 | 10.53% | 1,542,864 | $0.10 | $0.11 | $0.10 |
28 Oct 2024 | $0.10 | $0.01 | 11.11% | 3,565,382 | $0.09 | $0.11 | $0.09 |
25 Oct 2024 | $0.09 | $0.00 | 0.00% | 389,810 | $0.10 | $0.10 | $0.09 |
24 Oct 2024 | $0.09 | $-0.01 | -10.00% | 641,055 | $0.11 | $0.11 | $0.09 |
23 Oct 2024 | $0.10 | $0.00 | 0.00% | 51,793 | $0.10 | $0.11 | $0.10 |
22 Oct 2024 | $0.10 | $-0.02 | -17.39% | 452,047 | $0.11 | $0.11 | $0.10 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
04 Sep 2024 | Robert Iervasi | Buy | 179,200 | $15,076 |
On-market trade.
|
30 May 2024 | Jenelle Frewen | Buy | 190,740 | $25,944 |
On-market trade.
|
28 May 2024 | Robert Iervasi | Buy | 280,250 | $24,795 |
On-market trade.
|
29 Apr 2024 | Guy Headley | Sell | 3,500,000 | $385,000 |
On-market trade.
|
23 Apr 2024 | Guy Headley | Sell | 10,000,000 | $1,100,000 |
On-market trade.
|
15 Dec 2023 | Rodney Cocks | Issued | 1,241,808 | $335,288 |
Issue of securities.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Guy Rothwell Headley | Non-Executive Director | Dec 2021 |
Mr Headley has operated in the Australian Medical Cannabis space since 2016. He is a founding director of CDA Health Pty Ltd and has acted as a director of Burleigh Heads Cannabis Pty Ltd over the last eight years. He brings knowledge regarding medicinal cannabis sales, distribution and compliance in the heavily regulated industry. Prior to working in the cannabis space, Guy spent more than 15 years in the construction and development sector overseeing the procurement and management of multimillion dollar projects across New Zealand, Australia and the United Kingdom. Guy is also a founding Director and Chairman of the Emerging Therapeutics Association of Australia.
|
Ms Marcia Ani Matekino Walker | Non-Executive Director | Dec 2021 |
Dr Walker brings in Medical Governance and formerly served on the board of the New Zealand Medical Association and as a member of the General Practitioner Council of the NZMA, a member of the Medicines Classifications Committee for the Ministry of Health NZ and acts as a Medical Examiner for the Royal New Zealand College of General Practitioners. Previously, she acted as a Medical Advisor to the Rua BioScience (formerly Hikurangi Hemp Company) and as Treasurer for the New Zealand Resident Doctors Association. She is a Director and Treasurer of advocacy group General Practitioners Aotearoa and acts as the Medical Director of The Cosmetic Clinic New Zealand.
|
Ms Jenelle Lee Frewen | Non-Executive Director | Sep 2022 |
Mr Frewen is a government strategist and Cabinet-level adviser with more than two decades of experience spanning complex policy development and implementation in highly regulated industries. She has advised a range of business clients on strategic communications, public affairs and regulatory policy. Jenelle has experience working at all three levels of government in Australia and in new areas of policymaking in technology, broadband and cyber safety. Jenelle also spent time in her early career working as a communications and media adviser in the private sector.
|
Mr Robert Iervasi | Non-Executive ChairmanNon-Executive Director | Feb 2024 |
Mr Iervasi as the former Group CEO and Director of Asahi Beverages, Robert led a diversified consumer products / FMCG business with more than $5 billion in annual revenue and over 5,000 employees, including a manufacturing footprint. Prior to this, he served as the Group COO and CFO and General Counsel of Asahi for over eight years, managing Finance, Shared Business Services, Legal, Risk Strategy and Information Technology, as well Sales, Marketing, Supply Chain and Science and Innovation. Robert has successfully driven profitability and growth across multiple categories, brands and channels. In 2020, he identified and executed the acquisition by Asahi of Carlton & United Breweries. Robert brings experience and expertise in governance, finance, law, and innovation to Vitura.
|
Mr Thomas Godfrey Howitt | Chief Financial OfficerCompany SecretaryInterim CEO | Aug 2020 |
-
|
Thomas Godfrey Howitt | Chief Financial OfficerCompany SecretaryInterim CEO |
-
|
|
Nicola M. Swarbrick | Chief Operating Officer |
-
|
|
Ryan Tattle | Chief Revenue Officer |
-
|
|
Stefan Schmidt | Chief Technology Officer |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Elizabeth Sarah Jansen <Stanford Investment Trust> | 118,757,765 | 20.62% |
Guy Rothwell Headley | 95,548,772 | 16.59% |
Cronos Global Holdings Inc. | 55,176,065 | 9.58% |
Matua Hasyo Charlie Jansen <Whanau Family Trust> | 44,117,428 | 7.66% |
NewSouthern Investment Holdings 1 Pty Ltd <NewSouthern Investment Trust 1> | 21,000,000 | 3.65% |
NewSouthern Investment Holdings A Pty Ltd | 18,441,007 | 3.20% |
Citicorp Nominees Pty Limited | 13,225,910 | 2.31% |
HSBC Custody Nominees (Australia) Limited | 11,284,879 | 1.96% |
Ashanna Pty Ltd | 10,766,897 | 1.87% |
Melbourne Securities Corporation Limited <BV1 Fund A/C> | 9,000,000 | 1.56% |
Stone Group Pty Ltd <Stone Children A/C> | 6,377,765 | 1.11% |
UBS Nominees Pty Ltd | 5,833,174 | 1.01% |
EJ Watson (Medical) Pty Ltd <The EJ Watson Med S/F A/C> | 5,000,000 | 0.87% |
Jessimine Jansen | 4,253,379 | 0.74% |
Hektares SG Holdings Pte Ltd | 4,050,940 | 0.70% |
Daniel Francis Birch <BES A/C> | 3,766,498 | 0.65% |
Craig Graeme Chapman <Nampac Discretionary A/C> | 3,500,000 | 0.61% |
Ryan Tattle | 3,451,189 | 0.60% |
Robert Charles Hussey | 3,000,000 | 0.52% |
William David Copland and Susan Mary Copland David Copland Super fund A/C> | 2,484,000 | 0.43% |